Microbeads: a novel multiparticulate drug delivery technology for increasing the solubility and dissolution of celecoxib

References

• Speiser PP. Poorly soluble drugs, a challenge in drug delivery. In: Müller RH, Benita S, Böhm B, eds. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publishers; 1998:5–28
   Google Scholar
• Thompson D, Chaulbal MV. Cyclodextrins (CDS) – excipients by definition, drug delivery systems by function (part I: injectable applications). Drug Deliv Technol 2000;2:34–38
   Google Scholar
• Lee J. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches, experimental evidences and theory. Curr Nanosci 2005;1:237–243
   PubMed Web of Science ®Google Scholar
• Avrahami M, Aserin A, Garti N. Crystallization of celecoxib in microemulsion media. J Dispers Sci Technol 2007;28:1228–1235
   Web of Science ®Google Scholar
• Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003;4:36--44
   Google Scholar
• Homar M, Ubrich N, El Ghazouani F, et al. Influence of polymers on the bioavailability of microencapsulated celecoxib. J Microencapsul 2007;24:621–633
   PubMed Web of Science ®Google Scholar
• Maier TJ, Schilling K, Schmidt R, et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469–1478
   PubMed Web of Science ®Google Scholar
• Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293–297
   PubMed Web of Science ®Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Res 1998;58:409–412
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, Lanas, A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121–132
   PubMed Web of Science ®Google Scholar
• Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effects of food and site of absorption. J Pharmacol Exp Ther 2001;297:638–645
   PubMed Web of Science ®Google Scholar
• Rawat S, Jain SK. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2004;57:263–267
   PubMed Web of Science ®Google Scholar
• Saha RN, Sajeev C, Jadhav PR, et al. Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. J Pharm Biomed Anal 2002;28:741–751
   PubMed Web of Science ®Google Scholar
• Gibson L. Lipid-based excipients for oral drug delivery. In: Haus DJ, ed. Oral lipid-based formulations – enhancing the bioavailability of poorly water-soluble drugs. New York: Informa Healthcare; 2008:227–254
   Google Scholar
• Cannon JB, Long MA. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilisation and delivery – Part II: Oral applications. In: Lui R, ed. Water-insoluble drug formulation. 2nd ed. Florida: Taylor and Francis; 2008:227–254
   Google Scholar
• EMA Scientific Discussion on Onsenal, 2004. [Online] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/000466/WC500044630.pdf [last accessed 20 Aug 2013]
   Google Scholar
• FDA Dissolution Method for Celebrex® Capsules, 2010. [Online] Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1 [last accessed 20 Aug 2013]
   Google Scholar
• Shakeel F, Faisal MS. Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib. Pharm Dev Technol 2010;15:53–56
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ray S, Ghosal SK, et al. Formulation design of self-microemulsying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004;27:1993–1999
   PubMed Web of Science ®Google Scholar
• Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine 2010;5:1595–1616
   PubMed Web of Science ®Google Scholar
• Song WH, Park JH, Yeom DW, et al. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation. Arch Pharm Res 2013;36:69–78
   PubMed Web of Science ®Google Scholar
• Asghar LFA, Chandra S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharmaceut Sci 2006;9:327–338
   PubMed Web of Science ®Google Scholar
• Homar M, Dreu R, Kerc J, Gasperlin M. Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core. J Microencapsul 2009;26:479–484
   PubMed Web of Science ®Google Scholar
• Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007;96:2686–2702
   PubMed Web of Science ®Google Scholar
• Muellar EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301–304
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Fuloria J. Cyclooxygenase 2 inhibitors and colon cancer. Ochsner J 2002;4:176–179
   PubMedGoogle Scholar